The Calantic Digital Solutions platform
The Calantic Digital Solutions platform

Image source: Bayer

Sponsored • Expansion to AI market

Improving quantification and productivity

Bayer recently announced the launch of Calantic Digital Solutions, a new platform delivering access to digital applications, including artificial intelligence (AI) enabled programs for medical imaging.

The offering contains tools which aid radiologists and their teams to improve prioritization, lesion detection, quantification, and productivity. By providing access to AI radiology applications through the Calantic Digital Solutions platform Bayer expands its portfolio beyond contrast media, medical devices, software, and services. 

With Calantic Digital Solutions, we are entering the fastest growing segment in the radiology market and taking the next step on our way from a product provider to a solution provider

Gerd Krueger

Gerd Krueger, Head of Radiology at Bayer Pharmaceuticals, said: ‘With Calantic Digital Solutions, we are entering the fastest growing segment in the radiology market and taking the next step on our way from a product provider to a solution provider, following our mission to provide an ecosystem of third-party and Bayer products to deliver state-of-the art disease-oriented solutions for radiologists and their teams.’ 

Calantic Digital Solutions is a suite of digital radiology AI-enabled applications which provide assistance at critical steps within a patient’s treatment journey. The vendor-neutral, cloud-hosted platform includes a growing number of applications designed to aid in prioritization, lesion detection and quantification, as well as apps that automate routine tasks and measurements, improve the radiology suites’ workflow, and free up time for radiology staff. 

The offering is orchestrated by body region and procedure, initially focusing on thoracic and neurological diseases, such as pulmonary nodule detection. Another area of application is the triage of potential intracerebral hemorrhage (ICH) and large vessel occlusions (LVO), both of which can be associated with stroke. More disease-specific application packages will be added moving forward, the company announces. Bayer provides services around installation, configuration, and training of the platform and its applications. First launch markets will include the US and several European countries, with more regions to follow. 

The company sees increasing demand for innovation powered by AI: aging populations and changing lifestyles are leading to an increase in chronic conditions such as cardiovascular disease and cancer. Consequently, the need for medical imaging to detect diseases, guide treatment decisions and support therapy planning is growing. AI is the technology to meet these challenges, Bayer concludes, as it comes with the value proposition to accelerate diagnosis and increase the throughput of radiological examinations. 

More information: 

Source: Bayer


Read all latest stories

Related articles


Article • Digital breast tomosynthesis

Transforming breast screening: The role of AI in improving reading workflow

While having more centers adopt digital breast tomosynthesis (DBT) for breast cancer screenings into their practice is a positive change, it also presents some challenges for…


News • Chest X-ray evaluation

Human readers still outperform AI in lung disease identification

Reports of AI gaining the upper hand in diagnostic imaging interpretation are piling up, but there are still areas where the eye of a trained human radiologist remains superior.


News • Ultrasound, MRI, medical IT

Esaote to showcase AI-enhanced imaging at ECR

Italian biomedical and imaging company Esaote will be present at the ECR radiology congress in Vienna on March 1st - 5th, Expo X5 - Booth 517, to show its latest ultrasound, MRI and medical IT.

Related products

Subscribe to Newsletter